Skip to main content
SpringerLink
Log in

Economic Impact of Migraine and Other Episodic Headaches in France

Data from the GRIM2000 Study

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: Migraine is a prevalent and incapacitating condition that affects individuals in the prime of their productive life, thus generating an economic burden for both society and healthcare systems. The direct annual healthcare costs of migraine in France were assessed over 10 years ago, and the current study updates these figures.

Objective: The objective of this study was to determine the economic cost (primarily direct costs) of migraine and other episodic headache in France based on a general population survey of headache, the GRIM2000 (Groupe de Researche Interdisciplinaire sur la Migraine).

Design: From a representative general population sample of 10 585 individuals aged ≥15 years in France in 1999, 1486 individuals experiencing headaches were identified and interviewed regarding healthcare resource consumption in the previous 6 months. By applying unit costs to the resource data, costings (in 1999 values) were determined for physician consultations, hospitalisation, medication use and diagnostic/laboratory tests, and evaluated from a healthcare system perspective. Information on absenteeism and lost productivity was derived from the Migraine Disability Assessment Score (MIDAS) questionnaire.

Results: The prevalence of migraine (including migrainous disorder) was determined to be 17%. Total annual direct healthcare costs were estimated to be €128 per individual with migraine in 1999, corresponding to €1044 million when extrapolated to all individuals experiencing migraine and aged ≥15 years. Around two-thirds of this cost accrued to the social security system (€698 million; €85 per individual). The total annual direct cost of other forms of episodic headache was much lower at €28 per individual (social security cost €18); with a prevalence of 9.2%, the annual national direct cost for other forms of episodic headache totalled €124 million. The principal cost element was physician consultations. However, it was found that many individuals had never consulted a physician for their headaches, and self-medication contributed substantially to the medication costs (the second greatest cost factor for migraine). The cost per individual rose steeply with increasing severity of headache.

Conclusion: The direct healthcare costs of migraine do not seem to have risen significantly over the past decade. A small minority of individuals with more severe headaches consume most of the healthcare resources devoted to migraine, while most individuals generate relatively low direct costs. The total annual direct costs in France for migraine are almost 10-fold higher than those of other episodic headache.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V
Fig. 2
Fig. 3
Table VI

Similar content being viewed by others

References

  1. Ferrari MD. The economic burden of migraine to society. Pharmacceconomics 1998; 13: 667–76

    Article  CAS  Google Scholar 

  2. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659–964

    PubMed  CAS  Google Scholar 

  3. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67–76

    Article  PubMed  CAS  Google Scholar 

  4. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29–35

    Article  PubMed  CAS  Google Scholar 

  5. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992; 32: 223–8

    Article  PubMed  CAS  Google Scholar 

  6. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131–7

    PubMed  CAS  Google Scholar 

  7. Michel P, Auray JP, Chicoye A, et al. Prise en charge des migraineux en France: coot et recours aux soins: evaluation econorruque de la migraine en France. J Econ Med 1993; 11: 71–80

    Google Scholar 

  8. Kryst S, Scherl E. A population-based survey if the social and personal impact of headache. Headache 1994; 34: 344–50

    Article  PubMed  CAS  Google Scholar 

  9. Lipton RE, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992; 152: 1273–8

    Article  PubMed  CAS  Google Scholar 

  10. Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of healthcare use. Neurology 1994; 44: S47–55

    Article  Google Scholar 

  11. Michel P, Pariente P, Duru G, et al. A population-based, nationwide, comparative survey of access to care in migraine in France. Cephalalgia 1996; 16: 50–5

    Article  PubMed  CAS  Google Scholar 

  12. Michel P, Dartigues JF, Lindoulsi A, et al. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997; 37: 71–8

    Article  PubMed  CAS  Google Scholar 

  13. Michel P, Dartigues JF, Duru G, et al. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 1999; 19: 503–10

    Article  PubMed  CAS  Google Scholar 

  14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1–96

    Google Scholar 

  15. Bateman DN. Triptans and migraine. Lancet 2000; 335: 860–1

    Article  Google Scholar 

  16. Leff RF, Sclar DA, Nemec NL. Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care 1997; 3: 117–22

    Google Scholar 

  17. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996; 36: 538–41

    Article  PubMed  CAS  Google Scholar 

  18. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002; 59: 232–7

    Article  PubMed  CAS  Google Scholar 

  19. Richard A, Henry P, Chazot G, et al. Qualité de vie et migraine: validation du questionnaire QVM en consultation hospitalière et en médecine générale. Therapie 1993; 48: 89–96

    PubMed  CAS  Google Scholar 

  20. Stewart WF, Lipton RE, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53: 988–94

    Article  PubMed  CAS  Google Scholar 

  21. El Hasnaoui A, Vray M, Richard A, et al. Assessing the severity of migraine: development of the MIGSEV scale. Headache 2003 Jun; 43 (6): 628–35

    Article  PubMed  Google Scholar 

  22. Vidal, Louis. Dictionnaire Vidal 1999. Paris: Paris Office De Vulgarisation Pharmaceutique, 1999

    Google Scholar 

  23. UCANSS [online]. Available from URL: http://www.ucanssJr/ucanss.nsn [Accessed 2004 Aug 25]

  24. Lantéri-Minet M, Auray JP, EI Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 2: 143–9

    Article  Google Scholar 

  25. Lantéri-Minet M, Lucas C, Chaffaut C. Comportements thérapeutiques des migraineux: Framig 2000 II. Douleur 2001; 2: 233–46

    Google Scholar 

  26. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64–9

    Article  PubMed  CAS  Google Scholar 

  27. Van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics 1995; 7: 170–9

    Article  PubMed  Google Scholar 

  28. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 812–8

    Google Scholar 

  29. Björk S, Roos P. Economic aspects of migraine in Sweden. Lund: Institute for Health Economics, 1991

    Google Scholar 

  30. Blau JN, Drummond MF, editors. Migraine. London: Office of Health Economics, 1991

    Google Scholar 

  31. Parry TG. The prevalence and costs of migraine in Australia. Centre for Applied Economic Research (CAER) working paper n° 1992/1 Kensingyon: University of New South Wales. 1992.

    Google Scholar 

  32. Lipton RE, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638–45

    Article  PubMed  CAS  Google Scholar 

  33. Reynaud M, Gaudin-Colombel AF, Le Pen C. Two methods of estimating health costs linked to alcoholism in France (with a note on social costs). Alcohol Alcohol 2001; 36: 89–95

    Article  PubMed  CAS  Google Scholar 

  34. Boyer P, Dardennes R, Even C, et al. Dépression et santé publique: données et réflexions. Paris: Masson, 1999, 117

    Google Scholar 

  35. Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45: S5-S12

    Article  Google Scholar 

  36. Thirouin I. Allergie respiratoire, asthme, environnerrent: un programme pluriannuel de santé publique. Echanges Santé Social 1994: 74

  37. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 2001; 56 Suppl. 1: S35–42

    Article  Google Scholar 

Download references

Acknowledgements

The GRIM2000 study was funded by Laboratoire GlaxoSmithKline, France. The authors have provided no information on other conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Hôpital Louis Mourier, Colombes, France

    André Pradalier

  2. Université Claude Bernard, Lyon, France

    Jean-Paul Auray, Kazem Alzahouri & Gérard Duru

  3. Laboratoire GlaxoSmithKline, Marly-le-Roi, France

    Abdelkader El Hasnaoui & Anne-François Gaudin

  4. Université de Bordeaux II, Bordeaux, France

    Jean-François Dartigues

  5. Hôpital Pellegrin, Bordeaux, France

    Patrick Henry

  6. Hôpital Pasteur, Nice, France

    Michel Lantéri-Minet

  7. Hôpital Roger Salengro, Lille, France

    Christian Lucas

  8. Hôpital Neurologique, Lyon, France

    Guy Chazot

Authors
  1. André Pradalier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Paul Auray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdelkader El Hasnaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazem Alzahouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-François Dartigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gérard Duru
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrick Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michel Lantéri-Minet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christian Lucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guy Chazot
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Anne-François Gaudin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to André Pradalier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pradalier, A., Auray, JP., El Hasnaoui, A. et al. Economic Impact of Migraine and Other Episodic Headaches in France. PharmacoEconomics 22, 985–999 (2004). https://doi.org/10.2165/00019053-200422150-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200422150-00003

Keywords

Search

Navigation